Assessment of changes in membrane properties of platelets from patients with chronic myeloid leukaemia in different stages of the disease

Blood Coagulation and Fibrinolysis

Volumn 25, Issue 2, 2014, Pages 142-150

  Popov, Viola M ^b   Vladareanu, Ana M ^a   Bumbea, Horia ^a   Kovacs, Eugenia ^a   Moisescu, Mihaela Georgeta ^a   Onisai, Minodora ^a   Iordache, Maria Minodora ^a   Savopol, Tudor ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Endocrinology Department   (Romania)

Author keywords

BCR ABL transcript; chronic myeloid leukaemia; fluidity of platelet membrane; platelet aggregation; platelet membrane; platelet receptors; reactive oxygen species

Indexed keywords

AGED; BLOOD PLATELETS; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOPLASM STAGING; PLATELET AGGREGATION; PROGNOSIS; PROSPECTIVE STUDIES; REACTIVE OXYGEN SPECIES;

EID: 84894048149     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328365776f     Document Type: Article

References (39)

1. Vignini A, Moroni C, Nanetti L, Raffaelli F, Cester A. Alterations of platelet biochemical and functional properties in newly diagnosed type 1 diabetes: a role in cardiovascular risk? Diabetes Metab Res Rev 201;27:277-285.
2. Cocchi M, Tonello L, Lercker G. Fatty acids, membrane viscosity, serotonin and ischemic heart disease. Lipids Health Dis 2010;9:97.
3. Nanetti L, Vignini A, Raffaelli F, Moroni C, Silvestrini M, Provinciali L, Mazzani L. Platelet membrane fluidity and Na+/K+ ATPase activity in acute stroke. Brain Res 2008;1205:21-26.
4. Kozubski W, Swiderek M, Kloszewska I, Gwozdzinski K, Watala C. Blood platelet membrane fluidity and the exposition of membrane protein receptors in Alzheimer disease (AD) patients: preliminary study. Alzheimer Dis Assoc Disord 2002;16:52-54.
5. Watala C, Golański J, Boncler MA, Pietrucha T, Gwoździński K. Membrane lipid fluidity of blood platelets: a common denominator that underlies the opposing actions of various agents that affect platelet activation in whole blood. Platelets 1998;9:315-327.
6. Maurice P, Waeckel L, Pires P, Sonnet P, Lemesle M, Arbeille B, et al. The platelet receptor for type III collagen (TIIICBP) is present in platelet membrane lipid microdomains (rafts). Histochem Cell Biol 2006;125:407-417.
7. Vlaçdaçreanu AM, Popov VM, Radeşi S, Onisâi M, Bumbea H. Role of reactive oxygen species in platelet function in normal and chronic myeloproliferative disorders. Romanian J Biochem 2008;45:221-232.
8. Neelakantan P, Marin D, Laffan M, Goldman J, Apperley J, Milojkovic D. Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy. Haematologica 2012;97:1444.
9. Kim MS, Lee DH, Lee YR, Kim DK, Bae SH. Acaseof subdural hematoma in patient with chronic myeloid leukemia treated with high-dose imatinib mesylate. Korean J Hematol 2010;45:73-75.
10. Shimabukuro-Vornhagen A, Rothe A, Nogova L, Kochanek M, Scheid C, von Bergwelt-Baildon M. Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report. J Med Case Rep 2011;5:215.
11. Koptyra M, Cramer K, Slupianek A, Richardson C, Skorski T. BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress. Leukemia 2008;22:1969-1972.
12. Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, Winkler T, et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 2000;275:24273-24278.
13. Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia 2008;22:2020-2028.
14. Hollán S. Membrane fluidity of blood cells. Haematologia (Budap) 1996;27:109-127.
15. Begonja AJ, Teichmann L, Geiger J, Gambaryan S, Walter U. Platelet regulation by NO/cGMP signaling and NAD (P) H oxidase-generated ROS. Blood Cells Mol Dis 2006;36:166-170.
16. Schoene NW, Guidry CA. Genistein inhibits reactive oxygen species (ROS) production, shape change, and aggregation in rat platelets. Nutr Res 2000;20:47-57.
17. Conrad M, Sandin A, Fö rster H, Seiler A, Frijhoff J, Dagnell M, et al. 12/15-lipoxygenase-derived lipid peroxides control receptor tyrosine kinase signaling through oxidation of protein tyrosine phosphatases. Proc Natl Acad Sci U S A 2010;107:15774-15779.
18. Kubota Y, Tanaka T, Ohnishi H, Kitanaka A, Okutani Y, Taminato T, et al. Constitutively activated phosphatidylinositol 3-kinase primes platelets from patients with chronic myelogenous leukemia for thrombopoietin-induced aggregation. Leukemia 2004;28:1127-1137.
19. Baker RI, Manoharan A. Platelet function in myeloproliferative disorders: characterization and sequential studies show multiple platelet abnormalities, and change with time. Eur J Haematol 1988;40:267-272.
20. Mazzucato M, De Marco L, De Angelis V, De Roia D, Bizzaro N, Casonato A. Platelet membrane abnormalities in myeloproliferative disorders: decrease in glycoproteins Ib and IIb/IIIa complex is associated with deficient receptor function. Br J Haematol 1989;73:369-374.
21. Holme S, Murphy S. Platelet abnormalities in myeloproliferative disorders. Clin Lab Med 1990;10:873-888.
22. Liu D, Shen D, Zou P, Wei W, Wang A, Yang R. Redistribution of platelet membrane glycoprotein IV and release of intracellular alpha-granule thrombospondin in patients with chronic myelogenous leukemia. J Tongji Med Univ 1997;17:21-24.
23. Nishimura S, Manabe I, Nagasaki M, Kakuta S, Iwakura Y, Takayama N, et al. In vivo imaging visualizes discoid platelet aggregations without endothelium disruption and implicates contribution of inflammatory cytokine and integrin signaling. Blood 2012;119:45-56.
24. Gregg D, de Carvalho DD, Kovacic H. Integrins and coagulation: a role for ROS/redox signaling? Antioxid Redox Signal 2004;6:757-764.
25. Krötz F, Sohn H-Y, Pohl U. Players in the platelet game, reactive oxygen species. Arterioscler Thromb Vasc Biol 2004;24:1988-1996.
26. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: a Europe Against Cancer program. Leukemia 2003;17:2318-2357.
27. Serpa M, Sanabani SS, Dorliac-Llacer PE, Conchon M, Pereira TD, Nardinelli L, et al. Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission. BMC Blood Disord 2010;10:7.
28. Lakowicz JR. Fluorescence anisotropy in principles of fluorescence spectroscopy. New York: Springer Science Business Media; 2006.
29. Ng Ashley P. Resolution of platelet function defects with imatinib therapy in a patient with chronic myeloid leukaemia in chronic phase. Blood Coagul Fibrinolysis 2009;20:81-83.
30. Popov V, Bumbea H, Vladareanu AM, Saftoiu C, Radesi S, Nicolescu A. Alteration of platelet function in patients with chronic myeloid leukemia. J Thromb Haemostasis 2009;7:Su2.
31. Tiano L, Kantar A, Falcioni G, Littarru GP, Cherubini V, Fiorini R. Oxidative response and membrane modification of diabetic platelets challenged with PAF. Prostaglandins Other Lipid Mediat 2000;62:351-366.
32. Bermejo E, Alberto MF, Meschengieser SS, Lazzari MA. Assessment of platelet activation in myeloproliferative disorders with complementary techniques. Blood Coagul Fibrinolysis 2004;15:235-240.
33. Mohri H. Acquired von Willebrand disease and storage pool disease in chronic myelocytic leukemia. Am J Hematol 1986;22:391-401.
34. Emiliani C, Ciferri S, Mencarelli S, Mezzasoma AM, Momi S, Orlacchio A, Gresele P. Defective platelet beta-N-acetyl hexosaminidase content and release in chronic myeloproliferative disorders. Platelets 2006;17:20-29.
35. Villmow T, Kemkes-Matthes B, Matzdorff AC. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb Res 2002;108:139-145.
36. Popov VM, Vladareanu AM, Bumbea H, Radesi S, Iordache MM, Gologan R, et al. Membrane fluidity's role in platelet function in patients with myeloproliferative neoplasms. Blood Online 2010;116:5125.
37. Sallmyr A, Fan J, Rassool FV. Genomic instability in myeloid malignancies: Increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett 2008;270:1-9.
38. Quintás-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009;114:261-263.
39. Oda A, Miyakawa Y, Druker BJ, Ishida A, Ozaki K, Ohashi H, et al. Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin. Blood 1996;88:4304-4313.